RTI LNG1
Alternative Names: RTI-LNG1Latest Information Update: 06 Nov 2023
At a glance
- Originator Rejuvenation Technologies
- Class Antifibrotics; RNA
- Mechanism of Action Telomerase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis; Interstitial lung diseases
Most Recent Events
- 08 Sep 2023 Preclinical trials in Interstitial lung diseases in USA (Parenteral), prior to September 2023 (Rejuvenation Technologies pipeline, September 2023)
- 06 Sep 2023 Preclinical trials in Idiopathic pulmonary fibrosis in USA (Parenteral), prior to September 2023 (Rejuvenation Technologies pipeline, September 2023)
- 06 Sep 2023 Rejuvenation Technologies plans a clinical trial for Idiopathic pulmonary fibrosis and Interstitial lung diseases (Rejuvenation Technologies pipeline, September 2023)